How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

January 10, 2019

The Evolving Field of Treatment Modalities

Dr Morganna Freeman considers the future application of treatment modalities and how they might be combined for optimal results.

April 14, 2015

Clinical Validation of CancerTYPE ID

Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility.